Role of MicroRNAs on Age and Contraction-induced Skeletal Muscle Growth

Completed · Not applicable

Conditions studied: Sarcopenia

In brief

Sarcopenia is a predictor of functional-limitation, leading to loss of independence, lowered quality of life, and ultimately death. The impaired ability of aged skeletal muscle to adapt to anabolic stimulation may be a factor that contributes to sarcopenia. This project will provide novel insights into the role of microRNA in the attenuation of aging skeletal muscle to changes in gene expression after anabolic stimulation.

Key facts

Study ID

NCT02638454

Run by

Tufts University

People needed

30

Starts

2015-08-01

Expected to finish

2019-01-01

Last updated by the study team

2025-07-20

Who can join

Age: 20 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male and Female
• 20-30 or 70-85 years of age
• Sedentary: Must not participate in any regular exercise sessions (participants who walk regularly or walk for exercise are eligible)
• Individuals must confirm good health
• BMI must be between 19-35 kg/m2
• Individuals must be fluent in English
• Willing to come to the HNRCA laboratory for study visits
• Short Physical Performance Battery of less than 9 (70-85 years of age cohort)
• 10 subjects with Normal Muscle Mass and 10 subjects with Low Muscle Mass as determined by DXA scan (70-85 years of age cohort) Low Muscle Mass is defined as Class I Sarcopenia, Skeletal Muscle Index within 1 to 2 standard deviations from the sex-specific mean of young adults

You may not qualify if…

• Lost or gained 7.5% or more of their body weight in the past 6 months
• Acute or terminal disease
• Significant immune disorder
• Types I and II Diabetes mellitus
• Uncontrolled hypertension (>180/100 mmHg)
• Neuromuscular disease
• Subjects must also not be participating in any regular endurance or resistance training exercise during the previous six months.
• Mini-mental state examination (MMSE) score of <23
• Because of the DXA scan and the unknown risk associated with the muscle biopsy procedure, women who are pregnant, planning to become pregnant, or are breastfeeding will be excluded from the study.
• Subjects with a history of any of the following within the past 6 months will be excluded:
• Myocardial infarction in the past 6 months, or other symptomatic coronary artery disease.
• Surgery in previous 6 months
• Upper or lower extremity fracture in the previous 6 months
• Allergy to lidocaine
• Subjects currently taking any of the following drugs or classes of drugs will be excluded:
• Anticoagulant therapy (Warfarin, Coumadin, or Plavix)
• ACE inhibitors
• Drugs that affects neuromuscular function
• Angiotensin receptor blockers
• Androgen or estrogen therapy or other hormone replacement therapy
• Low dose aspirin with known cardiovascular disease (e.g.: reported coronary artery disease, peripheral vascular disease, or previous stroke, or history of transient ischemic attacks)
• Diabetes medications (ie. metformin, insulin therapy, thiazolidinediones, sulfonylureas etc.)
• Chronic corticosteroid therapy
• Laboratory blood test exclusions:
• Estimated GFR <30 mL/min/1.73m2

Where it is running

• Human Nutrition Research Center on Aging at Tufts University — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.